CN1150030C - 重组人甲胎蛋白及其用途 - Google Patents

重组人甲胎蛋白及其用途 Download PDF

Info

Publication number
CN1150030C
CN1150030C CNB96192764XA CN96192764A CN1150030C CN 1150030 C CN1150030 C CN 1150030C CN B96192764X A CNB96192764X A CN B96192764XA CN 96192764 A CN96192764 A CN 96192764A CN 1150030 C CN1150030 C CN 1150030C
Authority
CN
China
Prior art keywords
cell
rhuafp
purposes
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB96192764XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1179106A (zh
Inventor
�޲��ء�A��Ĭ����
罗伯特·A·默吉塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Mattienix Research & Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/377,309 external-priority patent/US5965528A/en
Priority claimed from US08/505,012 external-priority patent/US6331611B1/en
Application filed by Mattienix Research & Development Inc filed Critical Mattienix Research & Development Inc
Publication of CN1179106A publication Critical patent/CN1179106A/zh
Application granted granted Critical
Publication of CN1150030C publication Critical patent/CN1150030C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
CNB96192764XA 1995-01-24 1996-01-24 重组人甲胎蛋白及其用途 Expired - Lifetime CN1150030C (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US37731695A 1995-01-24 1995-01-24
US37731195A 1995-01-24 1995-01-24
US37731795A 1995-01-24 1995-01-24
US08/377,309 1995-01-24
US08/377,316 1995-01-24
US08/377,311 1995-01-24
US08/377,317 1995-01-24
US08/377,309 US5965528A (en) 1991-09-27 1995-01-24 Recombinant human alph-fetoprotein as an immunosuppressive agent
US08/505,012 1995-07-21
US08/505,012 US6331611B1 (en) 1991-09-27 1995-07-21 Expression and purification of cloned human alpha-fetoprotein

Publications (2)

Publication Number Publication Date
CN1179106A CN1179106A (zh) 1998-04-15
CN1150030C true CN1150030C (zh) 2004-05-19

Family

ID=27541364

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB96192764XA Expired - Lifetime CN1150030C (zh) 1995-01-24 1996-01-24 重组人甲胎蛋白及其用途

Country Status (7)

Country Link
EP (1) EP0805687A4 (xx)
JP (2) JPH10513347A (xx)
CN (1) CN1150030C (xx)
AU (1) AU700975B2 (xx)
CA (1) CA2211324C (xx)
HK (1) HK1010153A1 (xx)
WO (1) WO1996022787A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
WO1998035981A1 (en) * 1997-02-13 1998-08-20 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
EP1958503A3 (en) * 1999-01-06 2008-11-26 Merrimack Pharmaceuticals, Inc. Expression of secreted human alpha-fetoprotein in transgenic animals
EP1194536B1 (en) * 1999-07-12 2008-12-24 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
US7022892B1 (en) 1999-07-12 2006-04-04 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
EP1253930A4 (en) * 2000-02-10 2003-05-21 Univ California METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CANCER
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
WO2006031611A1 (en) * 2004-09-09 2006-03-23 Serometrix Llc Compositions and methods of using alpha-fetoprotein growth inhibitory peptides
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
JP2010513518A (ja) * 2006-12-19 2010-04-30 メリマック ファーマシューティカルズ インコーポレーティッド 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
WO2008113970A2 (en) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
CN105732795A (zh) * 2016-03-21 2016-07-06 海南医学院 一种获得人类甲胎蛋白的方法
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5486602A (en) * 1977-10-27 1979-07-10 Hoffmann La Roche Production of purified alpha 1 phetoprotein
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
EP0356399A3 (en) * 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5206153A (en) * 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby
AU2649592A (en) * 1991-09-25 1993-04-27 Wisconsin Alumni Research Foundation Complexes of anthracycline antibiotics with polyunsaturated fatty acids in lipid emulsions
CA2120131A1 (en) * 1991-09-27 1994-05-11 Robert A. Murgita Expression and purification of cloned human alpha-fetoprotein
DE59509887D1 (de) * 1994-09-26 2002-01-10 Infineon Technologies Ag Koppelanordnung zum optischen aneinanderkoppeln eines oeic-bausteins und optischer fasern

Also Published As

Publication number Publication date
HK1010153A1 (en) 1999-06-17
CN1179106A (zh) 1998-04-15
JPH10513347A (ja) 1998-12-22
AU4903596A (en) 1996-08-14
JP2008073041A (ja) 2008-04-03
EP0805687A4 (en) 2000-05-31
EP0805687A1 (en) 1997-11-12
AU700975B2 (en) 1999-01-14
CA2211324A1 (en) 1996-08-01
CA2211324C (en) 2012-07-10
WO1996022787A1 (en) 1996-08-01

Similar Documents

Publication Publication Date Title
CN1150030C (zh) 重组人甲胎蛋白及其用途
CN1107072C (zh) 编程性细胞死亡诱导分子ⅱ
CN1161152C (zh) 用于抑制血管生成的方法和组合物
CN1217956C (zh) 可溶性单链t细胞受体蛋白
CN1649895A (zh) 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
CN1549826A (zh) 治疗糖尿病的组合物和方法
CN1599754A (zh) 抗trail－r抗体
CN1130372C (zh) 肽衍生物
CN1543476A (zh) 用于将蛋白定向到胞外体的方法和化合物
CN1589279A (zh) 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
CN1201003C (zh) 脂肪细胞特异性蛋白质同系物
CN1561343A (zh) 可溶性t细胞受体
CN1817901A (zh) 治疗性肽和方法
CN1845995A (zh) 用于破坏宿主对外来抗原的耐受性的嵌合抗原
CN1156964A (zh) 新肽
CN1675362A (zh) Hla－a24限制性癌抗原肽
CN1925866A (zh) 细菌感染的治疗
CN1272884A (zh) 脂肪细胞特异性蛋白质同系物
CN1275085A (zh) 靶细胞的定向细胞溶解、引起细胞溶解的试剂和组合物以及可用于制备这些试剂的化合物
CN1582301A (zh) 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
CN1116305C (zh) 肽衍生物
CN1133049A (zh) 黑素瘤抑制蛋白质
CN1527723A (zh) 用cd2-结合剂治疗或预防皮肤病症的方法
CN1723032A (zh) 修饰蛋白质化合物毒性作用的组合物和方法
CN1170933C (zh) 促胃动素同系物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: MATTIE KNICKS RESEARCH AND DEVELOPMENT CO., LTD.

Free format text: FORMER OWNER: MCGILL UNIVERSITY

Effective date: 20030709

Owner name: MCGILL UNIVERSITY

Free format text: FORMER OWNER: ROBERT A MOJITA

Effective date: 20030709

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030709

Address after: Canada Quebec

Applicant after: MURGITA, ROBERT A.

Address before: Montreal, Canada

Applicant before: MCGILL University

Effective date of registration: 20030709

Address after: Montreal, Canada

Applicant after: MCGILL University

Address before: Montreal, Canada

Applicant before: Robert A. Murgita

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1010153

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: MERRIMAC MEDICINE CO., LTD.

Free format text: FORMER OWNER: MATTIE KNICKS RESEARCH AND DEVELOPMENT CO., LTD.

Effective date: 20061208

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20061208

Address after: Massachusetts, USA

Patentee after: MERRIMACK PHARMACEUTICALS Inc.

Address before: Quebec

Patentee before: MURGITA, ROBERT A.

CX01 Expiry of patent term

Granted publication date: 20040519

EXPY Termination of patent right or utility model